Home / Market News / $JNJ
benzinga Corporate Catalyst Impact 65/100 ● positive

Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease

Oct 19, 2026, 12:08 PM UTC · Primary ticker $JNJ

Johnson & Johnson announced positive one-year results from its Phase 3 FUZION study for TREMFYA in Crohn's disease patients with fistulas, showing maintained or improved remission. This data strengthens the drug's profile for a difficult-to-treat manifestation of the disease, potentially expanding its market opportunity and competitive positioning.

Johnson & Johnson announced one-year results from its Phase 3 FUZION study for TREMFYA, indicating the drug maintained or improved fistula remission in adults with Crohn's disease through 48 weeks. This is significant because fistulizing Crohn's disease is a particularly challenging manifestation to treat, and these positive long-term results build on previous 24-week data. This strengthens TREMFYA's competitive position in the inflammatory bowel disease market, potentially leading to increased market share and revenue for JNJ. For traders, this represents a positive long-term development for JNJ's pharmaceutical pipeline, reinforcing its growth prospects in a high-value therapeutic area, though the immediate market reaction might be moderate as this is an incremental data release rather than a new drug approval.

$JNJ positive Positive clinical trial results for key drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.